Global Sertraline Hydrochloride Tablet Market Size, Share and Trends Analysis Report, By Application (Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD)), Forecast (2022-2028)

The sertraline hydrochloride tablet market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Depression, panic attacks, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder (social phobia), and a severe type of premenstrual syndrome are all treated with sertraline hydrochloride tablets. Mood, sleep, appetite, and energy levels are all improved with this medicine. It is been used to reduce fear, anxiety, unpleasant thoughts, and panic attacks. It may also lessen the desire to conduct repetitive chores that are inconvenient in everyday life. Sertraline hydrochloride is a selective serotonin reuptake inhibitor (SSRI). It works by assisting in the restoration of a natural substance (serotonin) equilibrium in the brain. The rising prevalence of depression and anxiety are the major factors driving the growth of the global sertraline hydrochloride tablet market.

The global sertraline hydrochloride tablet market is segmented based on application. Based on application, the market is sub-segmented into MDD, OCD, PD, PTSD, SAD, and PMDD. Among these segments, the MDD segment is expected to propel the growth of the market due to the efficiency of these tablets in the treatment of MDD.

The market players are also contributing significantly to the market’s growth by adopting various strategies, including mergers, acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Co., Ltd. announced that they have entered into a global license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), a non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135. Non-racemic amisulpride (SEP-4199) is in Phase-3 clinical development for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression).

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Pfizer Inc., Cipla Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma Ltd., Lupin Pharmaceuticals Inc., and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?